Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study

Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling study

<p><strong>Background</p></strong> Cardiovascular disease incidence and mortality have declined across developed economies and granular up-to-date cost-effectiveness evidence is required for treatments targeting large populations. To assess the health benefits and cost-effect...

Descripció completa

Dades bibliogràfiques
Autors principals:	Mihaylova, B, Wu, R, Zhou, J, Williams, C, Schlackow, I, Emberson, J, Reith, C, Keech, A, Robson, J, Parnell, R, Armitage, J, Gray, A, Simes, J, Baigent, C
Format:	Journal article
Idioma:	English
Publicat:	Elsevier 2024

Ítems similars

Lifetime effects and cost-effectiveness of standard and higher-intensity statin therapy across population categories in the UK: a microsimulation modelling studyResearch in context
per: Borislava Mihaylova, et al.
Publicat: (2024-05-01)

Long-term cardiovascular risks and statin treatment impact on socioeconomic inequalities: microsimulation model
per: Wu, R, et al.
Publicat: (2023)

Lifetime effects and cost-effectiveness of statin therapy for older people in the United Kingdom: a modelling study
per: Mihaylova, B, et al.
Publicat: (2024)

Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant datasets
per: Mihaylova, B, et al.
Publicat: (2024)

Assessing long-term effectiveness and cost-effectiveness of statin therapy in the UK: a modelling study using individual participant data sets
per: Borislava Mihaylova, et al.
Publicat: (2024-12-01)

Statins for people at low risk of cardiovascular disease reply
per: Mihaylova, B, et al.
Publicat: (2012)

Prediction models for individual-level healthcare costs associated with cardiovascular events in the UK
per: Zhou, J, et al.
Publicat: (2023)

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
per: Mihaylova, B, et al.
Publicat: (2012)

Statins and diabetes - Authors' reply
per: Kearney, P, et al.
Publicat: (2008)

Cost-effectiveness of lowering LDL cholesterol with statins and ezetimibe in chronic kidney disease
per: Mihaylova, B, et al.
Publicat: (2019)

Statins and diabetes - Reply
per: Kearney, P, et al.
Publicat: (2008)

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
per: Emberson, J, et al.
Publicat: (2012)

Benefits of reducing LDL cholesterol among 18,686 patients with diabetes: Meta-analysis of 14 radomized trials of a statin versus control
per: Kearney, P, et al.
Publicat: (2006)

Efficacy and safety of statin therapy in older people: meta-analysis of individual participant data from 28 randomised controlled trials
per: Cholesterol Treatment Trialists' Collaboration, et al.
Publicat: (2019)

Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
per: Kearney, P, et al.
Publicat: (2008)

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis
per: Reith, CA, et al.
Publicat: (2024)

Misrepresentation of statin safety evidence.
per: Armitage, J, et al.
Publicat: (2014)

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
per: Reith, C, et al.
Publicat: (2022)

Effect of statins on ventricular arrhythmic events: a collaborative meta-analysis of randomised controlled trials
per: Rahimi, K, et al.
Publicat: (2009)

Lessons from the controversy over statins - Authors' reply.
per: Armitage, J, et al.
Publicat: (2016)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials
per: Cholesterol Treatment Trialists' Collaboration, et al.
Publicat: (2016)

Effect of statins on atrial fibrillation: a collaborative meta-analysis of randomised controlled trials
per: Rahimi, K, et al.
Publicat: (2009)

Pharmacogenomics of statin therapy: any new insights in efficacy or safety?
per: Hopewell, J, et al.
Publicat: (2014)

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease
per: Schlackow, I, et al.
Publicat: (2017)

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
per: Baigent, C, et al.
Publicat: (2010)

Safety and efficacy of statins - Authors' reply
per: Collins, R, et al.
Publicat: (2017)

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
per: Cholesterol Treatment Trialists' (CTT) Collaboration, et al.
Publicat: (2012-01-01)

Impact of CKD on household income
per: Morton, R, et al.
Publicat: (2017)

Interpretation of the evidence for the efficacy and safety of statin therapy
per: Collins, R, et al.
Publicat: (2016)

Effects of antiplatelet therapy after stroke due to intracerebral haemorrhage (RESTART): a randomised, open-label trial
per: Baigent, C, et al.
Publicat: (2019)

Statin Cost-Effectiveness in the United States for People at Different Vascular Risk Levels
per: Mihaylova, B, et al.
Publicat: (2009)

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy
per: Mihaylova, B, et al.
Publicat: (2016)

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised controlled trials of statins (vol 366, pg 1267, 2005)
per: Baigent, C, et al.
Publicat: (2008)

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
per: Mihaylova, B, et al.
Publicat: (2006)

Population-wide cohort study of statin use for the secondary cardiovascular disease prevention in Scotland in 2009–2017
per: Thalmann, I, et al.
Publicat: (2022)

Larger Effects of Fenofibrate on CVD in Marked Diabetic Dyslipidemia Are Not Explained by Higher Use of Statin Therapy: The FIELD Study
per: Simes, R, et al.
Publicat: (2009)

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
per: Baigent, C, et al.
Publicat: (2005)

Effects of Fenofibrate on Cardiovascular (CVD) Events in Patients with Type 2 Diabetes Mellitus (DM) after Adjustment for Statin Use and Other Drugs: the FIELD Study
per: Simes, J, et al.
Publicat: (2008)

Benefits of lowering cholesterol in chronic kidney disease Reply
per: Baigent, C, et al.
Publicat: (2011)

Efficacy and safety of cholesterol-lowering treatment - Reply
per: Baigent, C, et al.
Publicat: (2006)